KR20210149779A - Fc 영역 개변 항체의 정제 방법 - Google Patents

Fc 영역 개변 항체의 정제 방법 Download PDF

Info

Publication number
KR20210149779A
KR20210149779A KR1020217035897A KR20217035897A KR20210149779A KR 20210149779 A KR20210149779 A KR 20210149779A KR 1020217035897 A KR1020217035897 A KR 1020217035897A KR 20217035897 A KR20217035897 A KR 20217035897A KR 20210149779 A KR20210149779 A KR 20210149779A
Authority
KR
South Korea
Prior art keywords
ser
val
pro
lys
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217035897A
Other languages
English (en)
Korean (ko)
Inventor
데쓰야 와카바야시
유이치로 시미즈
마사히로 후쿠나가
에이지 마지마
Original Assignee
추가이 세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 추가이 세이야쿠 가부시키가이샤 filed Critical 추가이 세이야쿠 가부시키가이샤
Publication of KR20210149779A publication Critical patent/KR20210149779A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020217035897A 2019-04-10 2020-04-09 Fc 영역 개변 항체의 정제 방법 Pending KR20210149779A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2019-074738 2019-04-10
JP2019074738 2019-04-10
PCT/JP2020/015904 WO2020209318A1 (ja) 2019-04-10 2020-04-09 Ｆｃ領域改変抗体の精製方法

Publications (1)

Publication Number Publication Date
KR20210149779A true KR20210149779A (ko) 2021-12-09

Family

ID=72752051

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217035897A Pending KR20210149779A (ko) 2019-04-10 2020-04-09 Fc 영역 개변 항체의 정제 방법

Country Status (13)

Country Link
US (1) US20220213140A1 (https=)
EP (1) EP3954696A4 (https=)
JP (1) JP7583411B2 (https=)
KR (1) KR20210149779A (https=)
CN (1) CN113906042A (https=)
AU (1) AU2020273072B2 (https=)
BR (1) BR112021020204A2 (https=)
CA (1) CA3136398A1 (https=)
IL (1) IL286982A (https=)
MX (1) MX2021012251A (https=)
SG (1) SG11202110986YA (https=)
TW (2) TW202509054A (https=)
WO (1) WO2020209318A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
TWI812066B (zh) 2010-11-30 2023-08-11 日商中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
CN114773470A (zh) 2015-02-05 2022-07-22 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
TWI693940B (zh) 2016-08-05 2020-05-21 日商中外製藥股份有限公司 Ｉｌ-８相關疾病之治療用或預防用組成物
CN115850408A (zh) * 2022-09-01 2023-03-28 西安蓝晓科技新材料股份有限公司 一种多肽、融合型多聚体蛋白质及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05504579A (ja) 1990-10-17 1993-07-15 ザ・ウエルカム・ファウンデーション・リミテッド 精製イムノグロブリン
JP2007252368A (ja) 2006-02-21 2007-10-04 Protenova Co Ltd イムノグロブリン親和性リガンド
WO2007114319A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 抗体の血中動態を制御する方法
WO2015034000A1 (ja) 2013-09-04 2015-03-12 プロテノバ株式会社 イムノグロブリン結合ドメイン多量体
WO2017104783A1 (en) 2015-12-18 2017-06-22 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
EP0628639B1 (en) 1991-04-25 1999-06-23 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
DE69333823T2 (de) 1992-03-24 2006-05-04 Cambridge Antibody Technology Ltd., Melbourn Verfahren zur herstellung von gliedern von spezifischen bindungspaaren
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
CA2194907A1 (en) 1994-07-13 1996-02-01 Kouji Matsushima Reshaped human antibody against human interleukin-8
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
CN103172731A (zh) 2004-07-15 2013-06-26 赞科股份有限公司 优化的Fc变体
DK1817340T3 (da) 2004-11-12 2012-08-13 Xencor Inc Fc-varianter med ændret binding til fcrn
CN103555733A (zh) 2005-01-05 2014-02-05 F-星生物技术研究与开发有限公司 分子中互补决定区以外的区域中工程改造了的具有结合特性的合成免疫球蛋白结构域
WO2007097361A1 (ja) * 2006-02-21 2007-08-30 Protenova Co., Ltd. イムノグロブリン親和性リガンド
AU2008304748C1 (en) 2007-09-26 2014-06-12 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
RU2529951C2 (ru) 2007-12-26 2014-10-10 Ксенкор, Инк. ВАРИАНТЫ Fc С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ C FcRn
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
JP5229888B2 (ja) * 2008-09-30 2013-07-03 独立行政法人産業技術総合研究所 弱酸性域での易解離性を向上したプロテインａ変異型タンパク質及び抗体捕捉剤
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
EP3029066B1 (en) 2010-07-29 2019-02-20 Xencor, Inc. Antibodies with modified isoelectric points
TWI812066B (zh) 2010-11-30 2023-08-11 日商中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
WO2012132067A1 (ja) 2011-03-30 2012-10-04 中外製薬株式会社 抗原結合分子の血漿中滞留性と免疫原性を改変する方法
WO2012133349A1 (ja) * 2011-03-25 2012-10-04 株式会社カネカ アフィニティー分離マトリックス用タンパク質
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
EP3680251A1 (en) 2011-09-30 2020-07-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules for promoting elimination of antigens
EP2857419B1 (en) 2012-05-30 2021-01-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for eliminating aggregated antigens
EP3795215A1 (en) 2012-05-30 2021-03-24 Chugai Seiyaku Kabushiki Kaisha Target tissue-specific antigen-binding molecule
US20160031985A1 (en) 2013-03-15 2016-02-04 Katherine S. Bowdish Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
JP6153801B2 (ja) 2013-07-23 2017-06-28 旭化成ホームズ株式会社 ノズル
JP2015185254A (ja) 2014-03-20 2015-10-22 日立マクセル株式会社 非水電解質二次電池
KR101860280B1 (ko) * 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05504579A (ja) 1990-10-17 1993-07-15 ザ・ウエルカム・ファウンデーション・リミテッド 精製イムノグロブリン
JP2007252368A (ja) 2006-02-21 2007-10-04 Protenova Co Ltd イムノグロブリン親和性リガンド
WO2007114319A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 抗体の血中動態を制御する方法
WO2015034000A1 (ja) 2013-09-04 2015-03-12 プロテノバ株式会社 イムノグロブリン結合ドメイン多量体
WO2017104783A1 (en) 2015-12-18 2017-06-22 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use

Also Published As

Publication number Publication date
AU2020273072A1 (en) 2021-12-09
CN113906042A (zh) 2022-01-07
CA3136398A1 (en) 2020-10-15
EP3954696A1 (en) 2022-02-16
BR112021020204A2 (pt) 2021-12-07
JP7583411B2 (ja) 2024-11-14
EP3954696A4 (en) 2023-07-26
TW202104244A (zh) 2021-02-01
MX2021012251A (es) 2021-11-12
IL286982A (en) 2021-12-01
US20220213140A1 (en) 2022-07-07
WO2020209318A1 (ja) 2020-10-15
JPWO2020209318A1 (https=) 2020-10-15
TW202509054A (zh) 2025-03-01
SG11202110986YA (en) 2021-11-29
AU2020273072B2 (en) 2026-01-22

Similar Documents

Publication Publication Date Title
JP7583411B2 (ja) Ｆｃ領域改変抗体の精製方法
CN110234355B (zh) 单体人IgG1 Fc和双特异性抗体
JP7826243B2 (ja) アルブミン融合タンパク質を精製する方法
US20210047387A1 (en) Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species
CN110312734B (zh) 抗体分离能力改善的Fc结合性蛋白质及使用其的抗体的分离方法
JP7736688B2 (ja) 多重特異性抗原結合分子を製造するための方法
CN104640561A (zh) 包含轻链和重链的选择性配对的免疫球蛋白构建体
KR20110079693A (ko) 단일 도메인 항원 결합 분자의 정제 방법
CN106414495A (zh) 抗体处理方法
WO2019023097A1 (en) ASYMMETRIC BISPECIFIC ANTIBODIES AND THEIR USE
CN119698294A (zh) 结合γ-δT细胞受体的变体抗体
JP7788379B2 (ja) プロテインａアフィニティークロマトグラフィーを用いた生理活性ペプチドの精製方法
EP4400514A1 (en) Bispecific antibody comprising a heterodimer based on mhc proteins
HK40061321A (en) Method for purifying fc region-modified antibody
Shukla et al. Downstream processing of Fc fusion proteins, bispecific antibodies, and antibody–drug conjugates
Jung et al. Mass Production of Full‐Length IgG Monoclonal Antibodies from Mammalian, Yeast, and Bacterial Hosts
OA21635A (en) Bispecific Antibody Comprising A Heterodimer Based On Mhc Proteins.

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P12 Request for amendment of application rejected

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P12-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P12-X000 Request for amendment of application rejected

St.27 status event code: A-2-2-P10-P12-nap-X000